This extension of the synthetic lethal approach to MTAP and MAT2a inhibition provides a new potential therapy for colorectal carcinomas (CRCs) as only 2% of human CRCs are MTAP−/− (20). This evidence concerns the gene MAT2A and colorectal carcinoma.